Physician profile
Mary Mccormick
NPI 1568693133
$5,640.33
in general payments reported to CMS, 2019-2025
48 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $223 · 2021: $950 · 2022: $939 · 2023: $995 · 2024: $917 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.08 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $800.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $726.61 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $392.91 | 2019-2024 | |
| Astellas Pharma US INC | $371.85 | 2019-2025 | Veozah |
| Lilly USA, LLC | $327.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.05 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $249.20 | 2019-2025 | Breztri, Airsupra |
| Pfizer INC. | $240.51 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.11 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $165.59 | 2019-2023 | |
| Amgen INC. | $155.13 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $154.92 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $143.00 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $140.18 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Idorsia Pharmaceuticals US INC | $139.60 | 2023-2025 | Quviviq, Quviviq |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.